인공후두라는 의료기기는 후두절제술을 받은 사람이 말을 되찾을 수 있도록 도와줍니다. 후두절제술은 후두(성대)를 제거하는 수술입니다. 후두절제술은 암이나 기타 후두와 관련된 의학적 문제로 인해 시행되는 경우가 많습니다. 후두를 제거한 환자는 자연적으로 성대를 잃게 되어 말하기가 어려워집니다. 인공후두 기기는 발성의 대안을 제공하는 데 매우 중요합니다.
시간이 지남에 따라 기술 개발은 인공후두 기기의 기능과 디자인을 개선하여 후두 절제술 환자의 치료 결과를 개선했습니다. 인공후두를 효율적으로 사용하는 방법을 배우기 위해서는 언어치료가 필요하며, 언어치료사(SLP)의 도움을 받아야 합니다. 환자는 SLP와 함께 인공후두를 사용하여 대화와 의사소통 능력을 향상시키기 위해 SLP와 협력합니다. 인공후두에 사용되는 장치는 마모나 파손으로 인한 세척 및 교체를 포함한 정기적인 관리가 필요합니다.
중요한 종양인 후두암의 예후를 개선하기 위해서는 특히 고위험군에 대한 적절한 예방 및 진단 방법의 개발이 필수적입니다. 발성, 연하, 호흡, 사회적 관계, 정신 건강은 모두 후두 전절제술로 인해 큰 영향을 받아 삶의 질에 악영향을 미칩니다. 식도발성(ES)과 기관식도발성(TES)은 후두전절제술 환자에게 사용되는 두 가지 주요 재활방법으로, TES는 수술로 인공후두를 삽입하고 폐에서 나오는 공기를 인공후두를 통해 식도로 보내어 발성하는 방법이고, ES는 인두식도를 통해 발성하는 방법입니다.
자동 발성 밸브(ASV)를 사용하여 핸즈프리로 정상적인 발성을 할 수 있도록 하는 것이 후두절제술 후 언어치료의 최종 목표입니다. 손가락으로 스트로마를 가리킬 수 없기 때문에 양손이 자유로워져 빠른 언어 반응이 가능해져 장애에 대한 집중도가 높아집니다.
Inhealth Technologies는 Blom-Singer Dual Valve Indwelling Voice Prosthesis의 두 개의 밸브에 산화은을 재료의 방부제로 주입합니다. 보조 밸브는 일차 밸브가 고장난 경우에도 작동하도록 설계되어 유체 누출을 막는 데 도움이 됩니다. 브롬-싱어 이중 밸브 인공 성대는 표준 또는 대형 기관 / 식도 플랜지를 사용할 수 있으며, TEP의 2 차 치료 또는 교체 치료에 사용하기위한 삽입 / 세척 장치 및 비 멸균 인공 성대가 포함되어 있습니다.
큰 장벽 중 하나는 환자와 의료진이 인공후두 기기에 대해 잘 모른다는 것입니다. 또한, 일부 지역에서는 최첨단 기술 및 전문가 치료에 대한 접근이 제한되어 있습니다. 특히 보험이 충분하지 않은 환자나 의료 자원이 부족한 지역에서는 인공후두 기기 및 관련 의료 절차에 대한 높은 비용이 큰 장벽으로 작용합니다. 인공후두를 효율적으로 사용하기 위해서는 전문가의 음성 재활이 필요한데, 환자들에 따라서는 시간이 오래 걸리고 어려운 경우도 있습니다. 이러한 선택은 복잡성 때문에 환자들이 선택하지 않는 경우도 있습니다.
Medical devices called voice prosthesis devices assist people who have had laryngectomy surgeries in regaining their speech. A laryngectomy is a surgical surgery in which the larynx (voice box) is removed. This is frequently done in response to cancer or other larynx-related medical issues. Patients who have their larynx removed lose their natural vocal cords, making it hard for them to speak. Devices for voice prostheses are crucial in offering a substitute for vocalization.
Over time, technological developments have enhanced the functionality and design of vocal prosthesis devices, improving the outcomes for laryngectomy patients. With the aid of a speech-language pathologist (SLP), speech therapy is necessary to learn how to utilize a vocal prosthesis efficiently. To improve their speech and communication abilities using their device, patients engage with an SLP. Devices used for voice prostheses need routine care, including cleaning and replacement due to wear and tear.
The development of adequate preventative and diagnostic methods, particularly in high-risk populations, is crucial for the prognosis of laryngeal cancer, an important oncological entity. Speech, swallowing, breathing, social relations, and emotional health are all significantly impacted by total laryngectomy, which also has an adverse effect on quality of life. Esophageal speech (ES) and tracheoesophageal speech (TES) are the two primary rehabilitation methods used with complete laryngectomy patients. In contrast to TES, which involves surgically implanting a vocal prosthesis that permits air from the lungs to be directed via the prosthesis into the esophagus to make sound, ES uses the pharyngoesophageal segment to produce sound.
Achieving regular hands-free speech with an automated speaking valve (ASV) is the ultimate goal of speech therapy after a laryngectomy. The ASV automatically closes during tracheoesophageal speaking, negating the need to use a finger or hand to occlude the tracheostoma. Because the patient cannot point with his finger at his stoma when using an ASV, it frees up his hands, enables quick verbal response, and lessens the focus on his impairment.
Inhealth Technologies provides silver oxide placed in two valves of the Blom-Singer Dual Valve Indwelling Voice Prosthesis as a material preservative. The secondary speaking valve is designed to function even if the primary valve fails, helping to stop fluid leaking. Standard or large tracheal/esophageal flanges are available for the Blom-Singer Dual Valve Voice Prosthesis. Includes insertion/cleaning equipment and a non-sterile vocal prosthesis for use in secondary or replacement TEP treatments.
One big barrier is patients' and healthcare professionals' ignorance about vocal prosthetic equipment. Accessibility to cutting-edge technology and specialist care also be restricted in some areas. Particularly for patients without adequate insurance coverage or in areas with scarce healthcare resources, high costs connected with vocal prosthesis devices and related medical procedures can be a substantial barrier. It takes specialist speech rehabilitation, which can be time-consuming and difficult for some patients, to learn to utilize voice prosthesis devices efficiently. This option may not be chosen by patients because of its intricacy.
The global voice prosthesis devices market is segmented based on product type, end-user, and region.
When a person has had their larynx (voice box) removed during a laryngectomy treatment, they will utilize indwelling voice prosthesis devices, also known as indwelling tracheoesophageal voice prostheses (TVP). In order to improve speech and communication for laryngectomy patients, these devices are surgically placed.
Patients with laryngeal malignancies who have had laryngectomy may benefit from voice prosthesis (VPs), which are indwelling silicone valves used for speech therapy. A significant issue is the microbial biofilm buildup on VPs, which need frequent replacement and raises the risk of pneumonia and chest infections.
Microbial development is encouraged in the esophagus, where they are exposed to food, saliva, liquids, humidity, and temperatures around 37 °C. The inclusion of silver oxide (Blom Singer Advantage) and Teflon-like fluoroplastic (Provox ActiValve) into the VPs material to inhibit microbial colonization are just two strategies that have been suggested to lengthen the lifespan of the VPs.
North America has been a dominant force in the global voice prosthesis devices market. The most recent projections from the American Cancer Society for the number of new cases of laryngeal cancer in the United States in 2023 are 12,380 (9,900 in men and 2,480 in women). 750 women and 3,820 men will pass away from laryngeal cancer. About 35% of laryngeal malignancies develop above the vocal cords in the supraglottic region, while 60% begin in the glottis (the region containing the vocal cords).
A relatively tiny percentage of those who are diagnosed with laryngeal cancer are under the age of 55. Laryngeal cancer diagnoses typically occur in adults 66 and older.
The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global voice prosthesis devices market. The pandemic affected the manufacturing and distribution of medical goods, especially voice prosthesis, by upsetting worldwide supply networks. This might have caused brief shortages and delays in the availability of devices.
Numerous healthcare resources were diverted to deal with the pandemic's immediate crisis, which can have an impact on elective procedures and rehabilitation plans, particularly those using vocal prosthetic devices. During the pandemic, patients had reluctant to have elective surgery, which might have decreased the number of laryngectomy procedures and consequently the demand for voice prosthetic devices.
major global players in the market include: F. Hoffmann-La Roche Ltd., Sanofi, Novartis AG, Regeneron Pharmaceuticals, ICU Medical Inc., HEIMOMED Heinze, Atos Medical, and Servona Acclarent Inc.
The global voice prosthesis devices market report would provide approximately 46 tables, 53 figures, and 186 Pages.
LIST NOT EXHAUSTIVE